In recent years, EGFR tyrosine kinase gene mutations, as well as the EML4-ALK gene fusion, were determined to be a cause of NSCLC.19 This has led to the development of a variety of molecular-targeted drugs in preclinical and clinical studies. The gene discussed is ALK; the disease is non-small cell lung carcinoma.